Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
Lei ZhengDing DingBarish H EdilCarol JudkinsJennifer N DurhamDwayne L ThomasKatherine M BeverGuanglan MoSara E SoltJessica A HoareRaka BhattacharyaQingfeng ZhuArsen OsipovBeth OnnerKatrina A PurtellHongyan CaiRose ParkinsonAmy Hacker-PrietzJoseph M HermanDung T LeNilofer S AzadAna M C De Jesus-AcostaAlex B BlairVictoria KimKevin C SoaresLindsey ManosJohn L CameronMartin A MakaryMatthew J WeissRichard D SchulickJin HeChristopher L WolfgangElizabeth D ThompsonRobert A AndersElizabeth SugarDaniel A LaheruPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
It is safe and feasible to use a neoadjuvant immunotherapy approach for PDACs to evaluate early biologic responses. In-depth analysis of TLAs is warranted in future neoadjuvant immunotherapy clinical trials.